Disparity in checkpoint inhibitor utilization among commercially insured adult patients with metastatic lung cancer.

ABSTRACT:

Background

There is a lack of evidence from nationwide samples on the disparity of initiating immune checkpoint inhibitors (ICIs) after metastatic lung cancer diagnosis.

Methods

We identified metastatic lung cancer patients diagnosed between 2015 and 2020 from a large, nationwide commercial claims database. We analyzed the time from metastatic lung cancer diagnosis to ICI therapy using Cox proportional hazard models. Independent variables included county-level measures (quintiles of percentage of racialized population, quintiles of percentage of population below poverty, urbanity, and density of medical oncologists) and patient characteristics (age, sex, Charlson comorbidity index, Medicare Advantage, and year of diagnosis). All tests were 2-sided.

Results

A total of

SUBMITTER: Li M 

PROVIDER: S-EPMC9996212 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature